Author

R Abrahams

Observed names: Abrahams, R, R. Abrahams, Roger A Abrahams, Roger A. Abrahams, Roger Abrahams

Observed institutions: Mon Health Medical Center, Saint Francis Hospital & Medical Center, Pulmonary Associates

OpenAlex ID: A5020752681

Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)

2015 · Roland Buhl, François Maltais, et al. · European Respiratory Journal · 313

PDF

Tiotropium + olodaterol shows clinically meaningful improvements in quality of life

2015 · Dave Singh, Gary T. Ferguson, et al. · Respiratory Medicine · 173

CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial

2020 · Aili L. Lazaar, Bruce E. Miller, et al. · Respiratory Research · 78

PDF

Efficacy and safety of combining olodaterol Respimat® and tiotropium HandiHaler® in patients with COPD: results of two randomized, double-blind, active-controlled studies

2014 · Richard ZuWallack, Lisa Allen, et al. · International Journal of COPD · 59

PDF

Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis

2015 · Gary T. Ferguson, Matjaž Fležar, et al. · Advances in Therapy · 56

PDF

Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat® inhaler versus MDI

2010 · R. ZuWallack, M.C. De Salvo, et al. · Respiratory Medicine · 16

PDF

Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD

2013 · Roger Abrahams, Petra Moroni-Zentgraf, et al. · Respiratory Medicine · 14

PDF

Effects of baseline symptom burden on treatment response in COPD

2019 · Fernando J Martinez, Roger A Abrahams, et al. · International Journal of COPD · 11

PDF

Tiotropium + olodaterol fixed-dose combination shows clinically meaningful improvements in quality of life versus placebo

2015 · Dave Singh, Gary T. Ferguson, et al. · European Respiratory Journal · 6

P256 Safety Of Once-daily Tiotropium And Olodaterol Fixed-dose Combination Via The Respimat In Chronic Obstructive Pulmonary Disease In Two 1-year Studies

2014 · R. Buhl, R. Abrahams, et al. · Thorax · 6

PDF

Safety of once-daily tiotropium and olodaterol fixed-dose combination via the Respimat in chronic obstructive pulmonary disease in two 1-year studies

2015 · R Buhl, R Abrahams, et al. · Pneumologie · 4

Pooled Safety Analysis of Once-Daily Tiotropium and Olodaterol Fixed-Dose Combination via the Respimat in Patients With Chronic Obstructive Pulmonary Disease: Two 1-Year Studies

2014 · Roland Buhl, Roger Abrahams, et al. · CHEST Journal · 4

Author Correction

2015 · Roland Buhl, François Maltais, et al. · European Respiratory Journal · 3

PDF

Characteristics of Patients With and Without COPD Exacerbations During the Tiotropium + Olodaterol TONADO Studies

2016 · Roger Abrahams, Leif Bjermer, et al. · CHEST Journal · 2

PDF

Health Status of Patients With COPD Receiving the Combination of Olodaterol Respimat and Tiotropium HandiHaler Compared With Tiotropium: Results From Two Replicate, Randomized, Double-Blind Studies

2014 · Richard Zu Wallack, Lisa Allen, et al. · CHEST Journal · 2

PDF

Impact of grouping patients by 2017 GOLD strategy assessment criteria: a post hoc analysis of the TONADO and OTEMTO trials

2017 · Roland Buhl, François Maltais, et al. · European Respiratory Journal · 1

Tiotropium + Olodaterol Fixed-Dose Combination Therapy Provides Lung-Function Benefits Compared With Tiotropium Alone In Patients With GOLD A/B And C/D Chronic Obstructive Pulmonary Disease: Post Hoc Analyses Of Two 1-Year Studies

2016 · T Glaab, R Buhl, et al. · Pneumologie · 1

Tiotropium Plus Olodaterol Fixed-Dose Combination Therapy Provides Lung Function Benefits When Compared With Tiotropium Alone, Irrespective Of Prior Treatment With A Long-Acting Bronchodilator: Post Hoc Analyses Of Two 1-Year-Studies

2016 · T Greulich, R Buhl, et al. · Pneumologie · 1

S61 Analysis of the efficacy and safety of the combination of tiotropium + olodaterol in patients with COPD by previous usage of inhaled corticosteroids: Abstract S61 Table 1

2015 · S Korn, R Buhl, et al. · Thorax · 1

PDF

P123 Inhaled corticosteroid plus long-acting β2-agonist therapy is overused in the treatment of patients with chronic obstructive pulmonary disease: post hoc analyses of two 1-year studies: Abstract P123 Table 1

2015 · H Watz, GT Ferguson, et al. · Thorax · 1

PDF

Tiotropium + Olodaterol Provides Improvements in SGRQ and Dyspnea Compared With Monotherapy Components in Patients With COPD: Results From Four Randomized, Double-Blind Studies

2015 · Gary Ferguson, Emmanuelle Clerisme-Beaty, et al. · CHEST Journal · 1

Effect of Tiotropium + Olodaterol on the Use of Nighttime Rescue Medication in Patients With COPD: Results From Four Randomized, Double-Blind Studies

2015 · Roger Abrahams, Gary Ferguson, et al. · CHEST Journal · 1

Safety of the Combination of Olodaterol Respimat and Tiotropium HandiHaler Compared With Tiotropium: Results From Two Replicate 12-Week Studies

2014 · Roger Abrahams, Lisa Allen, et al. · CHEST Journal · 1

Combined Use of Olodaterol Respimat and Tiotropium HandiHaler Shows Additional Lung Function Improvement in COPD Compared With Tiotropium: Results From Two Randomized, Double-Blind Studies

2014 · Richard Zu Wallack, Lisa Allen, et al. · CHEST Journal · 1

Classifying patients as GOLD A-D using the 2017 strategy criteria: impact on efficacy by GOLD stage in the OTEMTO tiotropium+olodaterol clinical trials

2018 · F Fuchs, D Singh, et al. · Pneumologie

Works count: 39

Citation count: 756

H-index: 8

I10-index: 8